Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Depreciation & Amortization (CF) (2021 - 2025)

Historic Depreciation & Amortization (CF) for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $391000.0.

  • ARS Pharmaceuticals' Depreciation & Amortization (CF) rose 29100.0% to $391000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 67519.38%. This contributed to the annual value of $100000.0 for FY2024, which is 0.0% changed from last year.
  • Per ARS Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $391000.0 for Q3 2025, which was up 29100.0% from $279000.0 recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year Depreciation & Amortization (CF) high stood at $391000.0 for Q3 2025, and its period low was -$37000.0 during Q2 2022.
  • In the last 5 years, ARS Pharmaceuticals' Depreciation & Amortization (CF) had a median value of $100000.0 in 2023 and averaged $125611.1.
  • Per our database at Business Quant, ARS Pharmaceuticals' Depreciation & Amortization (CF) tumbled by 11770.33% in 2022 and then soared by 244545.45% in 2025.
  • ARS Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $204000.0 in 2021, then plummeted by 93.14% to $14000.0 in 2022, then surged by 614.29% to $100000.0 in 2023, then tumbled by 50.0% to $50000.0 in 2024, then soared by 682.0% to $391000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $391000.0 in Q3 2025, compared to $279000.0 in Q2 2025 and $280000.0 in Q1 2025.